XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

STOCKHOLDERS' EQUITY (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
STOCKHOLDERS’ EQUITY |
Schedule of Equity-Classified Warrants | The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2025:
|  | Number of Warrants |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years)
Total outstanding, December 31, 2024(1) |  | 1,765,070 |  | $ | 17.59 |  | 3.26
Granted |  | 747,200 |  |  | 3.56 |  | 2.00
Exercised |  | (385,200) |  |  | 0.01 |  | Indefinite
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, March 31, 2025 |  | 2,127,070 |  | $ | 15.85 |  | 2.60
Granted |  | - |  |  | - |  | -
Exercised |  | - |  |  | - |  | -
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, June 30, 2025 |  | 2,127,070 |  | $ | 15.85 |  | 2.10
Granted(2) |  | 6,338,788 |  |  | 1.65 |  | 3.31
Exercised |  | (878,264) |  |  | 0.001 |  | Indefinite
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, September 30, 2025 |  | 7,587,594 |  | $ | 5.82 |  | 2.82
Total exercisable, September 30, 2025 |  | 7,587,594 |  | $ | 5.82 |  | 2.82
(1) | Weighted average remaining contractual life at December 31, 2024 excludes 385,200 Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, for which 0 warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and September 30, 2025.
(2) | Weighted average remaining contractual life excludes 878,264 Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which 0 warrants remain outstanding and exercisable at September 30, 2025.
The following table presents a summary of the activity for the Company’s equity-classified warrants during the three and nine months ended September 30, 2024:
|  | Number of Warrants |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (Years)
Total outstanding, December 31, 2023 |  | 52,737 |  | $ | 369.98 |  | 4.47
Granted |  | 140,884 |  |  | 22.48 |  | 5.00
Exercised |  | (8,326) |  |  | 0.60 |  | Indefinite
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, March 31, 2024 |  | 185,295 |  | $ | 122.36 |  | 4.67
Granted |  | - |  |  | - |  | -
Exercised |  | (8,326) |  |  | 0.60 |  | Indefinite
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, June 30, 2024 |  | 176,969 |  | $ | 128.09 |  | 4.41
Granted(1) |  | 1,782,612 |  |  | 4.70 |  | -
Exercised |  | - |  |  | - |  | -
Forfeited |  | - |  |  | - |  | -
Expired |  | - |  |  | - |  | -
Total outstanding, September 30, 2024(1) |  | 1,959,581 |  | $ | 15.84 |  | 4.16
Total exercisable, September 30, 2024(2) |  | 756,680 |  | $ | 29.96 |  | 4.16
(1) | Weighted average remaining contractual life calculations exclude (i) 579,711 Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) 43,479 September 2024 Agent Warrants and 579,711 Series A Warrants issued September 2024 that expire five years from the Stockholder Approval Date, defined above, and (iii) 579,711 Series B Warrants issued September 2024 that expire eighteen months from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.
(2) | Weighted average remaining contractual life calculation excludes 579,711 exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration